Objective To explore the prevalence and related factors of female sexual dysfunction(FSD) in women with diabetic.Methods Female Sexual Function Index(FSFI) was used to investigate the prevalence of FSD in 336 women with diabetes.Logistic analysis was conducted between diabetic women with FSD and without FsD for related factom of diabetic FSD.Results Two hundred and fourty-four patients were found to have FSD.The prevalence was 72.6% .The Logistic analysis showed that FSD was significantly relaed to diahetic course and diabetic neuropathy.Conclusion The prevalence of FSD in diabetic women is significandy greater than non-diabetic women.Diabetic course and diabetic neuropathy play an important role in the development of FSD in diabetic women.

The major target of translational medicine is the rapid application of achievements in basic research to clinical medicine. How to carry out embedded subject service for translational medicine in academic library was thus described in aspects of constructing its information service platform, establishing its service team, and deciding its service methods.

Audiometry, Speech ; Humans ; Language

Animals ; Carcinoma, Non-Small-Cell Lung ; genetics ; metabolism ; Humans ; Lung Neoplasms ; genetics ; metabolism ; Molecular Imaging ; Mutation ; Positron-Emission Tomography ; RNA, Messenger ; metabolism ; Receptor, Epidermal Growth Factor ; biosynthesis ; genetics

Objective Liver metastasis model of human primary gastric lymphoma in nude mice was reproduced for an experiment to evaluate the inhibitory effect of cytokine-induced killer (CIK) cells on the growth and liver metastasis of primary gastric lymphoma. Methods Surgical orthotopic implantation of a histologically intact liver metastasis fragment derived from a surgical specimen of a patient with metastatic gastric lymphoma was initally implanted, in order to reprodueing a liver metastasis model of human primary gastric lymphoma. Peripheral blood mononuclear cells (PBMC), isolated by blood cell separator from healthy donors and patients with primary gastric lymphoma, were incubated in vitro. rhIFN-?, rhIL-2 and anti-CD3 McAb were added to PBMC in order to prepare CIK cells as well as lymphokine-activated killer (LAK) cells. CIK and LAK cells from different donors were used in treating gastric malignant lymphoma, so as to investigate the inhibitory effect of 2 kinds of effector cells on the growth of the tumor and liver metastasis. Results The liver metastasis model of human primary gastric malignant lymphoma in nude mice was successfully reproduced. After administration of different agents continuously for 20 days (0.3ml/d), the inhibitory rates of the following 4 groups, healthy donors LAK group (2?1010/ml), healthy donors CIK group (2?1010/ml), patients CIK group (1?1010/ml) and patient CIK group (2?1010/ml), were 39.28%, 53.57%, 40.38% and 56.42%, respectively. The liver metastasis rates in control group, healthy donors LAK group, healthy donors CIK group, patients CIK group (1?1010/ml) and patient CIK group (2?1010/ml), were 100.0%, 62.5%, 50.0%, 62.5% and 37.5%, respectively. Tumor weights of all treatment groups were lighter than that of saline group (P

OBJECTIVE:To observe the effects of bisoprolol combined with conventional triple therapy on the efficacy and re-lated indexes of patients with rheumatic heart valvular disease (RVD) combined chronic heart failure. METHODS:110 patients with RVD combined with chronic heart failure were randomly divided into observation group(55 cases)and control group(55 cas-es). All patients were treated with oxygen inhalation,anti-infection,correcting electrolyte imbalance,controlling arrhythmia,and giving digitalis drugs and diuretic drugs(it can be disabled after edema symptom being controlled);based on it,control group was given Enalapril tablet with initial dose of 2.5 mg,once to twice a day,then adjusted to 10-20 mg after 1 week,twice a day+20 mg Spironolactone tablet,once a day+10 mg Propranolol tablet,once a day. Observation group was additionally given Bisoprolol fuma-rate tablet initial dose of 1.25 mg,once a day,and then increased to 10 mg based on condition improved and tolerability after a meal,once a day. They were treated for 12 weeks. Clinical efficacy,and LVEF,LVEDD,LVESD,SBP,DBP,HR before and af-ter treatment and incidence of adverse reactions in 2 groups were observed. RESULTS:The total effective rate in observation group was significantly higher than control group,the difference was statistically significant (P<0.05). Before treatment,there were no significant differences in the LVEF,LVEDD,LVESD,SBP,DBP and HR between 2 groups(P>0.05). After treatment,LVEF in 2 groups were significantly higher than before,and observation group was higher than control group,LVEDD,LVESD,SBP, DBP and HR were significantly lower than before,and observation group was lower than control group,the differences were statis-tically significant(P<0.05). And there was no significant difference in the incidence of adverse reactions(P>0.05). CONCLU-SIONS:Based on conventional treatment,bisoprolol combined with conventional triple therapy shows good efficacy in the treat-ment of RVD combined chronic heart failure,it can improve cardiac function,with good safety.

Obesity-related diabetes and the metabolic syndrome are significantly related to increased adipose tissue mass.Understanding of the effect of adipose tissue on the metabolic regulation will play a key role in therapeutic strategies aimed to reduce obesity-induced insulin resistance and alleviate symptoms of the metabolic syndrome.Visfatin is a novel adipokine that appears to be preferentially produced by visceral adipose tissue and has insulin-mimetic actions.We discusse the relationship between visfatin and metabolic syndrome as well as future therapeutic strategies to these diseases.

Objective To investigate the mechanism of ursolic acid-induced apoptosis in human leukemia cells.Methods U937 cells were exposed to ursolic acid(UA) at various concentrations for 6 h and 12 h,or at 20 ?mol/L for different time intervals.Cells were stained with Annexin V/PI,and their apoptosis was determined through flow cytometry.Total protein extracts were prepared and subjected to Western blot assay using antibodies against PARP,C-Caspase-3,C-Caspase-9,Mcl-1,Bcl-2,Bcl-xL,Bax,and Bad.Parallel studies were performed in human leukemia cell lines Jurkat and HL-60.Results Exposure of U937 cells to UA resulted in increase in apoptosis in dose and time-dependent manners.We found that UA-induced lethality was associated with Caspase activation and PARP cleavage,and that UA-induced apoptosis was proceeded by the downregulation of Mcl-1.Jurkat and HL-60 leukemia cells in parallel studies exhibited apoptosis after UA exposure similar to those observed in U937 cells,although HL-60 cells were less sensitive than U937 cells in UA-induced apoptosis,PARP degradation as well as Caspases activation.Conclusion UA induces apoptosis in human leukemia cells through a process that involves Mcl-1 downregulation,followed by Caspase activation and PARP degradation.

AIM　Diclofenac potassium sustained-release tablets were developed as a gel matrix for using twice daily and evaluated in vitro release characteristics. METHODS　The formulations were screened according to the designed in vitro release rate by the use of HPMC as the gel matrix and the hydrophobic retarding agent to modify the release. RESULTS　The release was properly characterized by the diffusion mechanism, influenced by pH of the media, slightly affected by the basket rotating speed, without the influences from the pressure exerted during the tabletting procedure. CONCLUSION　The selected formulation of diclofenac potassium sustained-release tablets could ensure the desired in vitro release rate. In addition, it proved a good manufacturing reproducibility.

There is an insufficient supply in essential medicines, so the nation intends to reconsider the designated medicine production. But this will raise certain risks such as negative distribution, monopolies and weakening price signal. Thus the supporting methods should be proposed as below: improving the incentive of enterprises, the efficiency of designated products, and the government administration level to promote the development of the pharmaceutical market and improve the level of public health.